期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2010 ASCO年会上晚期NSCLC治疗进展 被引量：2

A Review of Progress in Treatment for Advanced Non-small Cell Lung Cancer in 2010 ASCO Report
原文传递
导出
摘要 2010年ASCO会议上,关于非小细胞肺癌的研究精彩纷呈,将影响今后NSCLC的临床实践及研究方向,全文就晚期NSCLC的有关治疗进展作一综述。
作者 范云
机构地区 浙江省肿瘤医院
出处 《肿瘤学杂志》 CAS 2010年第8期591-594,共4页 Journal of Chinese Oncology
关键词 癌 非小细胞肺 药物疗法 靶向药物 ASCO
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Muhicenter Italian Lung Cancer in the Elderly Study (MILES) phase Ⅲ randomized trial [J]. J Natl Cancer Inst, 2003, 95(5):362-372.
  • 2Hensing TA, Peterman AH, Schell M J, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage ⅢB or Ⅳ non-small cell lung carcinoma treated with carboplatin and paclitaxel [J]. Cancer, 2003, 98(4):779-788.
  • 3Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non- small-cell lung cancer: the cancer and leukemia group B (study 9730)[J]. J Clin Oncol, 2005, 23(1):190-196.
  • 4Quoix EA, Oster V, Westeel E, et al. Weekly paclitaxel with monthly carboplatin versus single-agent therapy in patients age 70 to 89:IFCT-0501 randomized phase Ⅲ study in advanced non-small cell lung cancer (NSCLC)[J]. Proc Am Soc Clin Oncol, 2010, 28(18s):946s.
  • 5Socinski MA, Bondarenko IN, Karaseva NA, et al. Results of a randomized, phase Ⅲ trial of nab-paclitaxel(nab-P) and carboplatin(C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)[J]. Proc Am Soc Clin Oncol, 2010, 28(18s):954s.
  • 6Mok TS, Wu YL, Thonqprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009, 361(10):947-957.
  • 7Massut Bi, Mora'n T, Porta R, et al. Muhicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: final results of the Spanish Lung Cancer Group (SLCG) trial [J]. J Clin Oncol. 2009 27:15s(Suppl): abstr 8023.
  • 8Gridelli C, Ciardiello F, Feld R, et al. International multicenter phase Ⅲ study of first-line erlotinib(E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-fine E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial[J]. Proc Am Soc Clin Oncol, 2010, 28(18s):540s.
  • 9Lee S, Rudd R, Khan I, et al. TOPICAL: Randomized Ⅲ trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy [J]. Proc Am Soc Clin Oncol, 2010, 28(18s):540s.
  • 10Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy[J]. J Clin Oncol, 2009, 27(9): 1394-1400.

同被引文献33

  • 1何赟,叶丽红.中医药治疗非小细胞肺癌研究进展[J].实用中医内科杂志,2009(4). 被引量：5
  • 2陆舜.晚期非小细胞肺癌患者个体化治疗的新突破[J].上海交通大学学报（医学版）,2011,31(3):261-264. 被引量：4
  • 3徐原林,胡秀峰.肺癌的内科治疗进展[J].中国实用医刊,2010,37(7):66-68. 被引量：2
  • 4Landreneau JP,Schuchert MJ, Weyant R,et al. Anatomic seg- mentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer ( NSCLC ) [ J ]. Surgery, 2014,155(2) :340 -346.
  • 5Zhao R, Diop-Bove N, Goldman ID. Enhanced receptor-medi- ated endocytosis and cytotoxicity of a folie acid-desacetylvin- blastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression [ J ]. Mol Pharmacol, 2014,85(2) :310 -321.
  • 6Langhaanner S. Rationale for the design of an oncology trial using a generic targeted therapy multidrug regimen for NSCLC patients without treatment options (Review) [ J ]. Oncol Rep,2013,30(4) :1 535 - 1 541.
  • 7Saadeddin A. Radiotherapy for NSCLC : review of conventional and new treatment techniques [ J ]. J Infect Public Health, 2012,5 ( Suppl 1 ) : S45 - S49.
  • 8Alvarez-Fernandez C, Perez-Amillas Q, Ruiz-Echeverria L, et al. Reduced folate carrier(RFC) as a predictive marker for re- sponse to pemetrexed in advanced non-small cell hmg cancer (NSCLC) [J]. Invest New Drugs,2014,32(2) :377 -381.
  • 9Riess JW, Nagpal S, Das M, et al. A case series of NSCLC patients with different molecular characteristics and choroi- dal metastases: improvement in vision with treatment inclu- ding pemetrexed and bevacizumab [ J ]. J Thorac Oncol, 2013,8(2) :e17 - e18.
  • 10Kreuter M, Vansteenkiste J, Fischer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine : the TREAT study [ J ]. Ann Oncol,2013,24 (4) :986 -992.

引证文献2

二级引证文献7

肿瘤学杂志
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部